Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-05-31

Clinical Trial Update: Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Patients With Chronic Urticaria (CU) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing 5 mg versus 20 mg desloratadine in chronic urticaria has completed, assessing dosing effects on skin lesions.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Desloratadine (desloratadine)

Snippet

Sponsor: Charite University, Berlin, Germany | Conditions: Chronic Urticaria | Phase 3 | Status: COMPLETED